Latest News and Press Releases
Want to stay updated on the latest news?
-
The Spectrum lawsuit alleges defendants misrepresented Pinnacle Study results for poziotinib, making public statements false and misleading.
-
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May...
-
Allegedly, Spectrum misled investors by overstating positive results of its Pinnacle Study on poziotinib for lung cancer, rendering statements false.
-
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May...
-
Spectrum allegedly misrepresented poziotinib trial results for lung cancer; statements were false and misleading throughout the class period.
-
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
-
NEW YORK, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
-
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
-
NEW YORK, Aug. 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
-
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...